# Does ARA-290 reduce inflammaging in older adults?

Canonical source: https://retacompare.com/research/does-ara-290-reduce-inflammaging-in-older-adults

Peptide Longevity Q&A · 2020-10-01


    Research indicates that ARA-290, also known as cibinetide, can ameliorate local inflammatory responses and reduce allogeneic T-cell responses in a mouse model, suggesting potential benefits in combating chronic low-grade inflammation, which is associated with aging and inflammaging.

 What the research shows

The study investigated the effects of ARA-290 (cibinetide) on islet allograft function in a preclinical model using streptozotocin-induced diabetic C57BL/6N mice. The mice were transplanted with islets from BALB/c mice, and the treatment with cibinetide was administered perioperatively and daily for 14 days. The research measured graft function through nonfasting glucose levels and assessed the expression of proinflammatory cytokines and proinsulin in the graft-bearing liver using quantitative polymerase chain reaction. The findings demonstrated that cibinetide significantly improved glycemic control immediately after transplantation and delayed the onset of allograft loss. Furthermore, when combined with a low dose of tacrolimus, cibinetide enhanced long-term graft survival.

 Why it matters for longevity

The implications of this research extend to the field of longevity, particularly concerning the role of chronic inflammation in aging. Inflammaging, characterized by low-grade chronic inflammation, is associated with various age-related diseases and conditions. By potentially reducing inflammatory responses, ARA-290 may contribute to improved healthspan and longevity, providing a therapeutic avenue to mitigate the effects of aging on the immune system and overall health. The ability of cibinetide to improve graft survival by addressing inflammation highlights its potential relevance in strategies aimed at enhancing longevity.

 Key findings at a glance

ARA-290 (cibinetide) improved islet graft function in a mouse model.

The peptide reduced local inflammatory responses in the liver after transplantation.

It significantly delayed the onset of allograft loss.

Combination treatment with low-dose tacrolimus enhanced long-term graft survival.

Cibinetide lowered the maturation of bone-marrow-derived immature dendritic cells.

The treatment reduced allogeneic T-cell responses in vitro.

 How ARA-290 works (background)

ARA-290 is an agonist of the innate repair receptor, which plays a critical role in modulating inflammatory responses. By binding to this receptor, ARA-290 can activate pathways that promote tissue repair and reduce excessive inflammation. In the context of islet transplantation, the peptide's ability to ameliorate inflammatory responses may help protect transplanted tissues from damage, thereby improving graft survival and function. The reduction in dendritic cell maturation and T-cell activation suggests a mechanism by which ARA-290 can influence immune responses, potentially offering benefits in managing conditions linked to chronic inflammation.

 Safety, caveats, and what we don't yet know

While the study provides promising insights into the effects of ARA-290 on inflammation and graft survival, it is important to note that these findings are based on preclinical models. The safety and efficacy of ARA-290 in human populations, particularly older adults, remain to be established through clinical trials. Further research is needed to determine the long-term effects, optimal dosing, and potential side effects of ARA-290 in various demographics. The translational potential of these findings to human health and longevity is still under investigation.

 Bottom line

In summary, ARA-290 shows potential in reducing inflammation associated with aging, which could contribute to improved healthspan and longevity. However, further research is necessary to confirm these effects in human populations.

 Related questions

 Can ARA-290 enhance recovery after surgery?

Research suggests that ARA-290 may have protective effects against inflammation, which could aid recovery processes post-surgery, though specific studies in surgical contexts are needed.

 What role does inflammation play in aging?

Chronic low-grade inflammation, known as inflammaging, is linked to various age-related diseases and conditions, contributing to the decline in healthspan and longevity.

 How does ARA-290 compare to other peptides for inflammation?

ARA-290's unique mechanism as an innate repair receptor agonist may differentiate it from other peptides, but comparative studies are necessary to evaluate its relative effectiveness.

 Source: PubMed · Transplantation · published 2020-10-01.

## Sources

- PubMed · Transplantation: https://pubmed.ncbi.nlm.nih.gov/32345869/